BR0008969A - Cloreto den-[2-hidróxi-3-(1-piperidinil)-(propóxi]piridina-1-óxido-3-carboximidoìla e seu uso no tratamento deresistência à insulina - Google Patents

Cloreto den-[2-hidróxi-3-(1-piperidinil)-(propóxi]piridina-1-óxido-3-carboximidoìla e seu uso no tratamento deresistência à insulina

Info

Publication number
BR0008969A
BR0008969A BR0008969-9A BR0008969A BR0008969A BR 0008969 A BR0008969 A BR 0008969A BR 0008969 A BR0008969 A BR 0008969A BR 0008969 A BR0008969 A BR 0008969A
Authority
BR
Brazil
Prior art keywords
treatment
piperidinyl
propoxy
hydroxy
pyridine
Prior art date
Application number
BR0008969-9A
Other languages
English (en)
Inventor
Maria Kurthy
Katalin Biro
Karoly Nagy
Laszlo Urogdi
Zita Csakai
Eno Szilbereky
Tamas Mogyorosi
Magdolna Torok
Andras Komaromi
Ede Marvanyos
Mihaly Barabas
Mihalyne Kardos
Oltan Nagy
Laszlo Koranyl
Melinda Nagy
Original Assignee
Biorex Kutato Fejlesztoe Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kutato Fejlesztoe Kft filed Critical Biorex Kutato Fejlesztoe Kft
Publication of BR0008969A publication Critical patent/BR0008969A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: "CLORETO DEN-[2-HIDRóXI-3-(1-PIPERIDINIL)PROPóXI]PIRIDINA-1-óXIDO-3-CARBOXIMIDOìLA E SEU USO NO TRATAMENTO DERESISTêNCIA à INSULINA". A invenção refere-se a cloreto deN-[2-hidróxi-3-(1-piperidinila)propóxi]-piridina-1-óxido-3-carboximidoíla, seus estereoisómeros e a sais de adição ácidos destes,composições farmacêuticas contendo os mesmos, o uso destescompostos no tratamento de resistência à insulina patológica, epara o tratamento de condições patológicas associadas com isto,para o tratamento de resistência à insulina patológica, e otratamento de condições patológicas associadas com isto, portratamento e prevenção simultâneos de complicações crónicasinduzidas por diabetes, especialmente retinopatia, neuropatia enefropatia e/ou com o aumento simultâneo da neurorregeneraçãoperiférica patologicamente diminuída causada por diabetes emétodos de tratamento.
BR0008969-9A 1999-02-26 2000-02-24 Cloreto den-[2-hidróxi-3-(1-piperidinil)-(propóxi]piridina-1-óxido-3-carboximidoìla e seu uso no tratamento deresistência à insulina BR0008969A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9900475A HUP9900475D0 (en) 1999-02-26 1999-02-26 O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
PCT/HU2000/000015 WO2000050403A1 (en) 1999-02-26 2000-02-24 N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance

Publications (1)

Publication Number Publication Date
BR0008969A true BR0008969A (pt) 2001-11-27

Family

ID=90014224

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008969-9A BR0008969A (pt) 1999-02-26 2000-02-24 Cloreto den-[2-hidróxi-3-(1-piperidinil)-(propóxi]piridina-1-óxido-3-carboximidoìla e seu uso no tratamento deresistência à insulina

Country Status (27)

Country Link
US (1) US6649628B1 (pt)
EP (1) EP1163224B1 (pt)
JP (1) JP4689838B2 (pt)
KR (1) KR100676124B1 (pt)
AT (1) ATE237590T1 (pt)
AU (1) AU779096B2 (pt)
BG (1) BG65178B1 (pt)
BR (1) BR0008969A (pt)
CA (1) CA2360451C (pt)
CZ (1) CZ297386B6 (pt)
DE (1) DE60002187T2 (pt)
DK (1) DK1163224T3 (pt)
EE (1) EE04961B1 (pt)
ES (1) ES2193055T3 (pt)
HR (1) HRP20010584B1 (pt)
HU (1) HUP9900475D0 (pt)
IL (2) IL144866A0 (pt)
NO (1) NO319793B1 (pt)
PL (1) PL197692B1 (pt)
PT (1) PT1163224E (pt)
RS (1) RS50083B (pt)
RU (1) RU2250901C2 (pt)
SI (1) SI1163224T1 (pt)
SK (1) SK287063B6 (pt)
UA (1) UA72495C2 (pt)
WO (1) WO2000050403A1 (pt)
ZA (1) ZA200106488B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001583A2 (hu) 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
HU0103939D0 (en) * 2001-09-27 2001-11-28 Biorex Kutato Fejlesztoe Kft Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride
PL371251A1 (en) * 2002-01-11 2005-06-13 Biorex Kutato Es Fejlesztö Rt. Carboxamidine derivatives and their use in the treatment of vascular diseases
HUP0303584A3 (en) 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
US20080227813A1 (en) * 2006-09-26 2008-09-18 Jack Raymond Barber Pharmaceutical compositions and methods for treating diseases associated with neurodegeneration
PL2659904T3 (pl) 2008-06-26 2016-01-29 Orphazyme Aps Zastosowanie Hsp70 jako regulatora aktywności enzymatycznej
BRPI0919867A2 (pt) * 2008-11-18 2015-12-15 Santen Pharmaceutical Co Ltd agente terapeutico ou profilatico para uma doenca degenerativa coriorretiniana, e metodo profilatico ou terapeutico para uma doenca degenerativa coriorrentiniana
PL2646044T3 (pl) 2010-11-30 2020-03-31 Orphazyme A/S Sposoby zwiększenia aktywności wewnątrzkomórkowej Hsp70
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
HUP1100535A2 (en) 2011-09-26 2013-04-29 Bracelia Invest Ltd Pharmaceutical composition for enhancement of stem cell treatment
ES2691981T3 (es) * 2012-09-06 2018-11-29 Mcpharma Biotech Inc. Tratamiento de la diarrea y de la diarrea post-destete con almidón resistente de patata
CA2884777C (en) 2012-09-14 2018-02-27 Saint-Gobain Glass France Pane with an electrical connection element
WO2015015248A1 (en) * 2013-07-30 2015-02-05 Debreceni Egyetem 67% The use of compounds showing heat shock protein (hsp) co-inducing properties to enhance the insulin sensitizing effect in the treatment of type 2 diabetes
EP3922242A1 (en) * 2014-09-15 2021-12-15 Orphazyme A/S Arimoclomol formulation
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
EP3782624A1 (en) * 2016-04-29 2021-02-24 Orphazyme A/S Arimoclomol for treating glucocerebrosidase associated disorders
AU2018274176A1 (en) 2017-05-24 2020-01-16 Zevra Denmark A/S Heat shock protein inducers and frontotemporal disorders
BR112020024182A2 (pt) 2018-05-28 2021-03-30 Orphazyme A/S Métodos para detectar proteína de choque térmico 70, para diagnosticar uma doença apresentando um nível reduzido de proteína de choque térmico 70, para selecionar um paciente tendo uma doença apresentando um nível reduzido de hsp70, para monitorar progressão de doença em um indivíduo, para monitorar a eficácia de uma terapia para tratamento de uma doença, e, para ajustar a dosagem de um derivado de hidroxilamina de molécula pequena.
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
WO2021116487A1 (en) 2019-12-13 2021-06-17 Som Innovation Biotech, S.A. Compounds for use in the treatment of niemann-pick c disease
CN116075305A (zh) 2020-06-24 2023-05-05 柯姆药物丹麦股份公司 用于治疗戈谢病的阿瑞洛莫
EP4247792A1 (en) 2020-11-19 2023-09-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof
US20240115558A1 (en) 2020-12-24 2024-04-11 Zevra Denmark A/S Arimoclomol for the treatment of niemann pick disease, type c, in patients with er type missense mutations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUT78138A (hu) * 1995-12-22 2000-09-28 BIOREX Kutató és Fejlesztő Rt Hidroximsavszármazékot tartalmazó készítmény a növénytermesztés elősegítésére és alkalmazása
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells
HU220971B1 (hu) * 1997-04-03 2002-07-29 BIOREX Kutató és Fejlesztő Rt. Eljárás 0-(3-amino-2-hidroxi-propil)-hidroximsav-halogenidek előállítására
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké

Also Published As

Publication number Publication date
IL144866A0 (en) 2002-06-30
HRP20010584B1 (en) 2010-08-31
NO319793B1 (no) 2005-09-12
RU2250901C2 (ru) 2005-04-27
SK287063B6 (sk) 2009-10-07
RS50083B (sr) 2009-01-22
CZ20013053A3 (cs) 2002-01-16
PL350915A1 (en) 2003-02-10
HUP9900475D0 (en) 1999-04-28
CA2360451A1 (en) 2000-08-31
ATE237590T1 (de) 2003-05-15
CA2360451C (en) 2011-01-04
EE04961B1 (et) 2008-02-15
YU60301A (sh) 2004-05-12
PL197692B1 (pl) 2008-04-30
WO2000050403A1 (en) 2000-08-31
DE60002187T2 (de) 2003-12-11
SK11582001A3 (sk) 2001-12-03
IL144866A (en) 2007-07-04
EP1163224A1 (en) 2001-12-19
HRP20010584A2 (en) 2002-08-31
PT1163224E (pt) 2003-07-31
DE60002187D1 (de) 2003-05-22
SI1163224T1 (en) 2003-08-31
BG105837A (en) 2002-03-29
JP2002537384A (ja) 2002-11-05
UA72495C2 (uk) 2005-03-15
KR20010102410A (ko) 2001-11-15
ES2193055T3 (es) 2003-11-01
DK1163224T3 (da) 2003-08-04
AU779096B2 (en) 2005-01-06
JP4689838B2 (ja) 2011-05-25
EE200100447A (et) 2002-12-16
KR100676124B1 (ko) 2007-01-31
EP1163224B1 (en) 2003-04-16
CZ297386B6 (cs) 2006-11-15
US6649628B1 (en) 2003-11-18
AU3182400A (en) 2000-09-14
BG65178B1 (bg) 2007-05-31
NO20014103L (no) 2001-10-22
ZA200106488B (en) 2002-08-07
NO20014103D0 (no) 2001-08-23

Similar Documents

Publication Publication Date Title
BR0008969A (pt) Cloreto den-[2-hidróxi-3-(1-piperidinil)-(propóxi]piridina-1-óxido-3-carboximidoìla e seu uso no tratamento deresistência à insulina
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
BR0214988A (pt) S-enanciÈmero de um composto, composto, formulação farmacêutica, método de tratamento ou prevenção de distúrbios de lipìdeo, uso de um composto, método de tratamento ou prevenção de diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica
BR9911779A (pt) Benzotiofenos, benzofuranos e indóis úteis no tratamento de resistência à insulina e hiperglicemia
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
SE0001899D0 (sv) New compounds
BR9907866A (pt) Composição farmacêutica compreendendo uma combinação de metformina e fibrato, e seu uso para a preparação de medicinas destinadas a reduzir a hiperglicemia
BR0010746A (pt) Derivados heterocìclicos úteis com agentes anticâncer
BR0010498A (pt) Composições modernas de medicamentos à base de compostos anticolinergicamente ativos e beta-miméticos
BR0108893A (pt) Composição farmacêutica, composto e processo de preparação de compostos
BR0111913A (pt) Análogos de gabapentina para distúrbios do sono
BR0009486A (pt) Compostos que contêm uma amida, utilização desses compostos, composição farmacêutica, processo para o tratamento profilático ou terapêutico de, diabetes do tipo ii e processo para a preparação dos compostos
RU2001126126A (ru) N-[2-гидрокси-3-(1-пиперидинил)пропокси]пиридин-1-оксид-3-карбоксиимидоилхлорид и его применение при лечении невосприимчивости к инсулину
BRPI0408437A (pt) derivados de p-diaminobenzeno substituìdos, composição farmacêutica, e, uso da mesma
BR0113590A (pt) 7-oxo-piridopirimidinas
BR9906373A (pt) Compostos pirimidinona, composições farmacêuticas contendo os compostos e processos para a preparação dos mesmos
Bajwa et al. Use of Articaine in loco-regional anesthesia for day care surgical procedures
BR0010006A (pt) Utilização do saredutante e de seus sais farmaceuticamente aceitáveis para o preparo de medicamentos úteis no tratamento ou na prevenção do conjunto das perturbações do humor, das perturbações da adaptação ou das perturbações mistas ansiedade-depressão
BRPI9509819B8 (pt) benzamida enterocinética e composição farmacêutica compreendendo a mesma
BR0316131A (pt) Acetil-l-carnitina para a prevenção e/ou tratamento de neuropatias periféricas induzidas por agentes anti-câncer
BR0009101A (pt) 9a-azalidas com atividade antibacteriana
BR0312852A (pt) Emprego de cilobradina ou os sais farmaceuticamente aceitáveis desta para o tratamento ou prevenção de insuficiência cardìaca
MY129832A (en) Substituted thiophenes, processes for their preparation, their use as medicament or diagnostic and medicament comprising them
BRPI0406552A (pt) Uso de l-carnitina para o tratamento de doenças cardiovasculares
BR0214487A (pt) Composição farmacêutica que compreende uma combinação de metformina e um ácido 4-oxobutanóico, e o uso da mesma para o tratamento de diabetes

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2138 DE 27/12/2011.